<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tivozanib: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tivozanib: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tivozanib: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="131127" href="/d/html/131127.html" rel="external">see "Tivozanib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F55698626"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Fotivda</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F55596254"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Tyrosine Kinase Inhibitor;</li>
<li>
                        Antineoplastic Agent, Vascular Endothelial Growth Factor (VEGF) Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F55659062"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Withhold tivozanib for at least 24 days prior to elective surgery. Do not administer tivozanib for at least 2 weeks after major surgery and until adequate wound healing. Each 1.34 mg capsule contains 1.5 mg of tivozanib hydrochloride salt (equivalent to 1.34 mg of tivozanib); each 0.89 mg capsule contains 1 mg of tivozanib hydrochloride salt (equivalent to 0.89 mg of tivozanib). Dosing presented as tivozanib base.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ce178d26-1d2f-44fa-8218-4e3f73623fb4">Renal cell carcinoma, advanced, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal cell carcinoma, advanced, relapsed or refractory: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used in patients who have progressed on ≥2 prior therapies, including a VEGFR tyrosine kinase inhibitor (other than tivozanib or sorafenib), and may be an option in patients who have progressed on both immunotherapy and a VEGFR inhibitor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Atkins.1','lexi-content-ref-George.1','lexi-content-ref-31810797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Atkins.1','lexi-content-ref-George.1','lexi-content-ref-31810797'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>1.34 mg once daily on days 1 to 21 of a 28-day cycle until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31810797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31810797'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses:</i> If a dose is missed, resume dosing with the next scheduled dose. Do not administer 2 doses at the same time.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F55659064"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Kidney function estimated by Cockcroft-Gault formula.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Renal impairment prior to treatment initiation:</i></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥15 mL/minute: No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">End-stage renal disease: There are no dosage adjustments provided in the manufacturer's labeling (has not been established).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Renal toxicity during treatment:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Proteinuria (≥2 g per 24 hours): Withhold tivozanib until &lt;2 g per 24 hours, then resume at a reduced dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Nephrotic syndrome: Permanently discontinue tivozanib.</p></div>
<div class="block doha drugH1Div" id="F55659065"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (total bilirubin ≤ ULN with AST &gt; ULN or total bilirubin &gt;1 to 1.5 times ULN with any AST): No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate impairment (total bilirubin &gt;1.5 to 3 times ULN with any AST): Reduce dose to 0.89 mg once daily for 21 days of a 28-day cycle.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (total bilirubin &gt;3 to 10 times ULN with any AST): There are no dosage adjustments provided in the manufacturer's labeling (has not been established).</p></div>
<div class="block dot drugH1Div" id="F55659093"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Tivozanib Dose Reduction Levels for Adverse Reactions</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;text-align:center;">Dose reduction level</p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">Tivozanib dose</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Usual (initial) dose</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">1.34 mg on days 1 to 21 of a 28-day cycle</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">First dose reduction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">0.89 mg on days 1 to 21 of a 28-day cycle</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Tivozanib Dose Modifications for Adverse Reactions</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;text-align:center;">Adverse reaction</p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">Severity</p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">Management</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Control hypertension prior to tivozanib initiation. If tivozanib is discontinued, a drop in BP is expected and antihypertensive therapy should be reduced and/or interrupted as clinically appropriate (ESC [Lyon 2022]).</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> ASCO [Armenian 2017]; ESC [Lyon 2022].</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center" rowspan="4">
<p style="text-indent:0em;">Hypertension<sup>a</sup></p></td>
<td align="center" colspan="2">
<p style="text-indent:0em;">If indicated, initiate appropriate antihypertensive therapy to reduce the risk for cardiovascular complications.<sup>b</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold tivozanib for grade 3 hypertension that persists despite optimal antihypertensive therapy. Resume at a reduced dose when hypertension is controlled at ≤ grade 2.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue tivozanib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Hypertensive crisis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Discontinue tivozanib.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Cardiac failure</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold tivozanib until improvement to grade 0 or 1 or to baseline. Resume at a reduced dose <b>or</b> discontinue (depending on the severity and persistence of adverse reaction).</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue tivozanib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">GI toxicity (diarrhea, nausea, vomiting)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Any</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Initiate medical management prior to tivozanib therapy interruption or dose reduction.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Arterial thromboembolic events</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Any grade</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue tivozanib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Venous thromboembolic events</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Severe or life-threatening</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Discontinue tivozanib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hemorrhagic events</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue tivozanib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Reversible posterior leukoencephalopathy syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Any grade</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue tivozanib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Thyroid dysfunction (hypothyroidism or hyperthyroidism)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Any</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Treat hypothyroidism and hyperthyroidism to maintain euthyroid state before and during tivozanib therapy.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Wound healing complications</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Any</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold tivozanib until adequate wound healing. The safety of resuming tivozanib after resolution of wound healing complications is unknown.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Other adverse reactions</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Persistent or intolerable grade 2 or 3 adverse reactions or grade 4 laboratory abnormality</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold tivozanib until improvement to grade 0 or 1 or to baseline. Resume at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 4 adverse reaction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue tivozanib.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F55659063"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F55599350"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (44% to 45%; hypertensive crisis: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Palmar-plantar erythrodysesthesia (16%), skin rash (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum magnesium (26%), decreased serum phosphate (38%), decreased serum sodium (36%), hypothyroidism (8% to 24%), increased amylase (23%), increased serum calcium (15%), increased serum glucose (50%), increased serum potassium (26%), thyroid dysfunction (11%), weight loss (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Decreased appetite (39%), diarrhea (43%), increased serum lipase (32%), nausea (30%), stomatitis (21%; grades 3/4: 2%), vomiting (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hemoglobin (16%; grades 3/4: 1%), decreased platelet count (19%), hemorrhage (11% to 17%; grades 3/4: 3%), increased hemoglobin (19%), lymphocytopenia (25%; grades 3/4: 5%), prolonged partial thromboplastin time (26%; grades 3/4: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatobiliary disease (&lt;15%), increased serum alanine aminotransferase (30%), increased serum alkaline phosphatase (30%), increased serum aspartate aminotransferase (28%), increased serum bilirubin (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Delirium (&lt;15%), fatigue (67%), voice disorder (27%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (19%), osteonecrosis (&lt;15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (50%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (22%), dyspnea (15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Arterial thromboembolism (2%), cardiac failure (2%), ischemic heart disease (3%), venous thromboembolism (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperthyroidism (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Proteinuria (8%)</p></div>
<div class="block coi drugH1Div" id="F55596257"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F55658977"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac effects: Serious or fatal cardiac failure may occur. Tivozanib has not been studied in patients with symptomatic cardiac failure within the 6 months prior to tivozanib therapy initiation. Cardiac ischemia has also been reported, including ≥ grade 3 events and fatality due to ischemic stroke.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemorrhage: Serious or fatal hemorrhagic events have been reported. Tivozanib has not been studied in patients with significant bleeding within the 6 months prior to tivozanib therapy initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertension: Hypertension commonly occurred with tivozanib, including ≥ grade 3 events. The median time to onset of hypertension was 2 weeks (range: up to 192 weeks). Hypertensive crisis (including 1 fatality) was reported in a small number of patients. Tivozanib has not been studied in patients with systolic BP &gt;150 mm Hg or diastolic BP &gt;100 mm Hg.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrotoxicity: Proteinuria has occurred, including grade 3 events. Some patients who developed proteinuria also had acute kidney injury either concurrently or later during treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Reversible posterior leukoencephalopathy syndrome: Reversible posterior leukoencephalopathy syndrome (RPLS) may occur. Evaluate for RPLS by MRI scan in patients presenting with seizures, headaches, visual disturbances, confusion, or altered mental function.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolism: Arterial and venous thromboembolism have occurred, including fatalities. Tivozanib has not been studied in patients who had an arterial thrombotic event, myocardial infarction, or unstable angina within the 6 months prior to tivozanib therapy initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disorders: Thyroid dysfunction, including rare grade 3 or 4 events, has occurred. Hypothyroidism and hyperthyroidism were reported in ~8% and 1% of patients, respectively.</p>
<p style="text-indent:-2em;margin-left:4em;">• Wound healing complications: Wound healing complications may occur with medications that inhibit vascular endothelial growth factor signaling (including tivozanib).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Yellow dye: Tivozanib contains FD&amp;C Yellow No. 5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in some patients. While the incidence of tartrazine sensitivity in the overall population is low, it is frequently seen in patients who also have aspirin hypersensitivity.</p></div>
<div class="block foc drugH1Div" id="F55698627"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fotivda: 0.89 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine), fd&amp;c yellow #5 (tartrazine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fotivda: 1.34 mg</p></div>
<div class="block geq drugH1Div" id="F55698625"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F55724847"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Fotivda Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.89 mg (per each): $1,680.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.34 mg (per each): $1,680.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F55659096"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with or without food. Swallow whole with a glass of water; do not open the capsule.</p></div>
<div class="block hazard drugH1Div" id="F55658980"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Tivozanib may cause teratogenicity, reproductive toxicity, and has a structural/toxicity profile similar to existing hazardous agents.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations and institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note: </b>Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block use drugH1Div" id="F55596256"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Renal cell carcinoma, advanced, relapsed or refractory:</b> Treatment of relapsed or refractory advanced renal cell carcinoma in adults following ≥2 prior systemic therapies.</p></div>
<div class="block mst drugH1Div" id="F55658961"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Tivozanib may be confused with axitinib, cabozantinib, lenvatinib, PAZOPanib, regorafenib, SORAfenib, SUNItinib, tepotinib, tucatinib.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F55609830"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F55609827"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Androgens: Hypertension-Associated Agents may enhance the hypertensive effect of Androgens. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Angiogenesis Inhibitors (Systemic) may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Tivozanib.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Tivozanib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: May enhance the hypertensive effect of Hypertension-Associated Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F55658974"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status prior to treatment initiation.</p>
<p style="text-indent:0em;margin-top:2em;">Patients who may become pregnant should use effective contraception during therapy and for 1 month after the last dose of tivozanib. Patients with partners who may become pregnant should also use effective contraception during therapy and for 1 month after the last tivozanib dose.</p></div>
<div class="block pri drugH1Div" id="F55658975"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to tivozanib may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F55658976"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if tivozanib is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for 1 month after the last tivozanib dose.</p></div>
<div class="block mop drugH1Div" id="F55659098"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Kidney function (monitor for proteinuria prior to tivozanib initiation and periodically throughout therapy); hepatic function (baseline); thyroid function (baseline and periodically throughout treatment). Verify pregnancy status prior to treatment initiation (in patients who can become pregnant). Monitor BP (after 2 weeks and at least monthly thereafter); if receiving antihypertensive therapy, monitor for hypotension during tivozanib treatment interruptions. Monitor for signs/symptoms of cardiac failure, arterial or venous thromboembolic events (closely monitor patients at risk for or who have a history of thromboembolic events), and hemorrhagic events. Monitor for signs/symptoms of impaired wound healing or reversible posterior leukoencephalopathy syndrome. Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Additional cardiovascular monitoring:</i> Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking (ASCO [Armenian 2017]; ESC [Lyon 2022]). BP at each clinical visit (as well as daily home monitoring for first cycle, after dose increases, and every 2 to 3 weeks thereafter); baseline echocardiography in high- and very high-risk patients (repeat every 3 months during the first year and every 6 to 12 months thereafter); consider baseline echocardiography in low- and moderate-risk patients (consider repeating every 4 months during the first year and every 6 to 12 months thereafter for moderate-risk patients) (ESC [Lyon 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F55658982"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Tivozanib is a potent and selective vascular endothelial growth factor receptor (VEGFR) inhibitor (Rini 2020). Tivozanib inhibits phosphorylation of VEGFR-1, VEGFR-2, and VEGFR-3; it also inhibits other kinases (including c-kit and PDGFR β). Tivozanib inhibits angiogenesis, vascular permeability, and tumor growth of various tumor cell types.</p></div>
<div class="block phk drugH1Div" id="F55659006"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 123 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ≥99%, primarily to albumin.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Predominantly via CYP3A4.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 111 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 10 hours (range: 3 to 24 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces: 79% (26% as unchanged drug); urine: 12%.</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: 0.75 L/hour.</p></div>
<div class="block phksp drugH1Div" id="F55663462"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Tivozanib AUC<sub>tau</sub> increased by 1% and 62%, respectively, in patients with mild or moderate hepatic impairment (compared to subjects with normal hepatic function).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56522317"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Fotivda</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Fotivda</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Fotivda</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Fotivda</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Fotivda</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Fotivda</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Fotivda</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Fotivda</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Fotivda</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Fotivda</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Fotivda</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Fotivda</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Fotivda</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tivozanib-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Atkins.1">
<a name="Atkins.1"></a>Atkins MB. Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 23, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fotivda.1">
<a name="Fotivda.1"></a>Fotivda (tivozanib) [prescribing information]. Boston, MA: AVEO Pharmaceuticals Inc; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-George.1">
<a name="George.1"></a>George D, Jonasch E. Systemic therapy of advanced clear cell renal carcinoma. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 23, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update.<i> J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tivozanib-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J</i>. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tivozanib-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31810797">
<a name="31810797"></a>Rini B, Pal SK, Escudier BJ, et al. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. <i>Lancet Oncol.</i> 2020;21(1):95-104. doi:10.1016/S1470-2045(19)30735-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tivozanib-drug-information/abstract-text/31810797/pubmed" id="31810797" target="_blank">31810797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/</a>. Updated September 2016. Accessed March 12, 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 131053 Version 39.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
